Long Time Coming: Pediatric Gastroenterologists React to New

Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.

Related Keywords

Elizabeth Spencer , Riha Bhatt , Drug Administration , Vanderbilt University Medical Center , Icahn School Of Medicine At Mount Sinai , Regeneron Pharmaceutical , Biologics License Application , Priority Review , Icahn School , Mount Sinai , Mount Sinai Kravis Children , Priority Review Application , Pediatric Eosinophilic , Dupilumab , Dupixent , Eosinophilic Esophagitis , Gastroenterology ,